Improvement of rosacea by injection of platelet-rich plasma

Rosacea is a chronic facial inflammatory disease characterized by erythema, papules, telangiectasia, and recurrent flushing. Many studies have documented the crucial role that an immature immune system plays in the progression of rosacea. Various studies have illustrated the potential effectiveness of platelet-rich plasma (PRP) on the inhibition of inflammation. Although rosacea is a disease caused by inflammation accompanied by an immature immune system, there is no research explaining the effects of PRP on rosacea through the regulation of immunity and inflammation. The PRP was prepared using the SmartPReP2 APC+ in three participants who provided informed consent. The centrifuged PRP (total 4-5 ml) was then injected into the facial dermal area using a 26-gauge 5-cm cannula. In all three cases, the erythema in the cheek and chin area was severe, and telangiectasia was seen in the cheek preoperatively. Postoperatively, erythema and telangiectasia improved significantly during weeks 4 and 12. We believe this is the first article to document the potential therapeutic effects of PRP enriched with CD34 stem cells in the peripheral blood for the treatment of rosacea. In conclusion, PRP enriched with CD34 stem cells in the peripheral blood may have a potential additive therapeutic effect on rosacea via an immunomodulation effect. Long-term prospective follow-up studies are warranted to confirm the beneficial effect of PRP enriched with CD34 stem cells in the peripheral blood for the treatment of rosacea.